Tags: new | psoriasis | drug | fda | otezla

New Psoriasis Drug: FDA Approves Otezla for Expanded Use

By    |   Thursday, 25 Sep 2014 07:00 AM

A new psoriasis drug, Otezla, has been approved for expanded use to treat patients with moderate to severe plaque psoriasis, the U.S. Food and Drug Administration ruled this week.

The drug, known chemically as apremilast, is already approved for treating psoriatic arthritis, a type of arthritis associated with the skin disease, according to Reuters.

Urgent: Do You Approve Or Disapprove of President Obama's Job Performance? Vote Now in Urgent Poll

The drug is also being studied as a potential treatment for a type of spondylitis.

Celgene Corp forecast in March annual Otezla sales of $1.5 billion to $2 billion by 2017.

Psoriasis is a chronic inflammatory disease of the skin resulting from an uncontrolled immune response.

Urgent: Assess Your Heart Attack Risk in Minutes. Click Here.

© 2017 Newsmax. All rights reserved.

   
1Like our page
2Share
TheWire
A new psoriasis drug, Otezla, has been approved for expanded use to treat patients with moderate to severe plaque psoriasis, the U.S. Food and Drug Administration ruled this week.
new, psoriasis, drug, fda, otezla
126
2014-00-25
Thursday, 25 Sep 2014 07:00 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved